The Guardian and IEEE Spectrum Feature Ardent Cell Technology

The Cell Thermograft team was awarded BiomedX funding in 2013. Since then, the project has become a start-up named Ardent Cell Technologies, led by Dr. Brian Gillette (below). In late May, Dr. Gillette and his collaborators published a paper in Scientific Reports that described their fat burning technology.

 Dr. Brian Gillettte

Dr. Brian Gillettte

Here is how the technology would work: "An overweight person would go to a clinic for a simple procedure in which a small scrap of bad “white fat” tissue would be sucked out of his/her belly. Doctors would stick that piece of tissue into an automated bioreactor, where it would get a chemical bath for about three weeks. Within that machine, it would change into the good “brown fat” tissue that helps the body burn calories to stay warm. Then the patient would return to the clinic, and the scrap of tissue would be reinserted into his/her body. This transmogrified tissue would raise his metabolism and help him lose weight, even without the hard work of diet and exercise."

"In a paper published on Monday in Scientific Reports, Gillette and his collaborators describe their preliminary experiments. They showed that their conversion procedure, which doesn’t require any genetic engineering, works on both mouse and human fat tissue. They also injected converted tissue into mice, and showed that the tissue retained its brown fat qualities (rather than reverting to white fat) for the eight-week duration of the study." - Eliza Strickland, IEEE Spectrum Article

Since this publication in Scientific Reports, the technology has been featured in The Guardian, IEEE Spectrum, Newsweek, BBC Radio, and Newsday.  

Forbes and NBC feature VisionIdeale project

Forbes and NBC have featured our VisionIdeale project, awarded BiomedX funding in 2015. The publications focus on the non-invasive vision correction technique and the impact of our vision correction surgery in today's world where there is an increasing number of patients with shortsightedness. 

VisionIdeale.png

Principal Investigator Sinisa Vukelic "has developed a new non-invasive approach to permanently correct vision that shows great promise in preclinical models. His method uses a femtosecond oscillator, an ultrafast laser that delivers pulses of very low energy at high repetition rate, for selective and localized alteration of the biochemical and biomechanical properties of corneal tissue. The technique, which changes the tissue’s macroscopic geometry, is non-surgical and has fewer side effects and limitations than those seen in refractive surgeries. For instance, patients with thin corneas, dry eyes, and other abnormalities cannot undergo refractive surgery. The study, which could lead to treatment for myopia, hyperopia, astigmatism, and irregular astigmatism, was published May 14 in Nature Photonics." - Holly Evarts, Columbia Engineering

2018 AWARDS ANNOUNCED

We are extremely pleased to announce this year's newly funded projects in the Columbia Biomedical Technology Accelerator portfolio. 

Funds are awarded to perform a "killer experiment", that is, an experiment that will substantially remove risk and leave no doubt that the product will be an improvement over the status quo. 

CONGRATULATIONS to the following teams!

DENTAL MEDICINE

MySmileBuddy: Electronic counseling tool to stop tooth decay and reduce dental treatmentChristie Custodio-Lumsden, PhD, and Burton Edelstein, DDS, MPH; TLO: Cynthia Lang

DRUG DELIVERY

A Drug Delivery Injector for Highly Viscous Drug FormulationsOzgur Sahin, PhD; Richard D. Carvajal, MD, Eran Schenker, Research Scientist; TLO: Satish Rao

HAVA: Therapeutic OTC inhalant device to alleviate inflammation & pain of the upper aerodigestive tractSinisa Vukelic, PhD; Michael Pitman, MD; TLO: Sara Gusik

RADIOLOGY / IMAGING 

Dynamic Optical Tomographic Breast Imaging System (DOTBIS) for Predicting Cancer Therapy OutcomeAndreas Hielscher, PhD and Dawn Hershman, MD, MS; TLO: Satish Rao

 

To see all projects funded by BiomedX, click HERE.

2018 PITCH DAY

This year 18 teams were selected to participate in the BiomedX bootcamp focused on commercializing medical technologies. The course included 34 principal investigators (engineering, life sciences, clinical) and 23 graduate students (engineering, MBA, MD, DMD) enrolled for credit and embedded on the project teams.

On Tuesday, April 24th, teams of Columbia engineers, clinicians, scientists and students working to bring cutting-edge biomedical technologies to market will pitch their envisioned technologies and business opportunities to a panel of judges and invited guests for potential commercialization support.

Columbia BiomedX Pitch Day is the capstone event following a semester long “boot camp,” during which project teams explored two fundamental questions: 1) Does the envisioned product address a true unmet clinical need? and 2) Is there a viable business opportunity? These are the same questions judges will have in mind as they select projects to fund. 

We are excited about the 2018 applicant projects and look forward to seeing you on April 24th.

Please RSVP to attend pitch day.

WHEN

Tuesday, April 24, 2018 from 8:30 AM to 3:30 PM (EDT)

WHERE

Herbert Irving Comprehensive Cancer Center

1130 St. Nicholas Ave (Between 166th and 167th Strret)

ICRC Auditorium, 1st Floor

New York, NY 10032 (SEE MAP)

2017 Call for Pre-Proposals

Columbia Biomedical Technology Accelerator

We are very pleased to announce that the Columbia Biomedical Technology Accelerator is currently accepting Pre-Proposals for the next application cycle (i.e. 2018 funding).

All biomedical technologies with the potential to directly impact human health will be considered (e.g. therapeutic drugs and devices, medical imaging, monitoring devices, biosensors, biomaterials, and platform technologies). Most relevant are technologies in which the time to market can be achieved in 7 to 10 years. To be eligible, the project/technology must be an idea or invention based on Columbia intellectual property.

Eligible teams must include both an engineer/scientist and a clinician, and at least one PI must have a faculty appointment at Columbia. If you need an engineering or clinical collaborator, we may be able to facilitate introductions. Please email matchmaking requests to biomedx@columbia.edu by November 1, 2017. 

Pre-Proposals are due by Friday, December 1, 2017.

INFO SESSIONs

CUMC

Tuesday, October 3rd, 12pm, 622 W 168th Street, PH10-204 (Conference Room) [map] [Click here to RSVP]

MORNINGSIDE

Friday, October 6th, 12pm, Mudd 220B (Mech Eng Conference Room) [map] [Click here to RSVP]

 

If you have any questions, please email us at biomedx@columbia.edu.

For more information on the application process, click HERE

2017 AWARDS ANNOUNCED

We are extremely pleased to announce this year's newly funded projects in the Columbia Biomedical Technology Accelerator portfolio. 

Funds are awarded to perform a "killer experiment", that is, an experiment that will substantially remove risk and leave no doubt that the product will be an improvement over the status quo. 

CONGRATULATIONS to the following teams!

Cardiology

"VISIBLATE: A novel imaging system for real time assessment of ablation lesions during catheter ablation of cardiac arrhythmias" (Elisa Konofagou, BME; Elaine Wan, Medicine; TLO: Satish Rao)

Immunotherapy / Therapeutics

"IMMPERA: Stem cell therapy to reduce morbidity and mortality from graft-vs-host-disease in bone marrow transplant patients" (Holly Wobma, SEAS & College of Physicians and Surgeons; Gordana Vunjak-Novakovic, BME; Markus Mapara, Medicine; TLO: Beth Kauderer) 

"OncoShell: A rapid functional test of breast cancer drug sensitivity" (Laura Kaufman, Chemistry; Asja Guzman, Chemistry; Kevin Kalinsky, Medicine; TLO: Beth Kauderer)

Orthopedics

"MicrOA: A MicroCT-Based Structural Analysis System to Monitor and Assess Osteoarthritis" (X. Edward Guo, BME; Elizabeth Shane, Medicine; TLO: Richard Nguyen)

Psychiatry

"Aision: Prophylactic drugs to prevent the development of stress-induced mood and anxiety disorders" (Christine Denny, Psychiatry; Michael Grunebaum, Psychiatry; Rebecca Brachman, Neurology; TLO: Ron Katz)

Screening / Diagnostics / Monitoring

"inSensor: Novel device for reducing pulmonary complications in hospitalized patients by improving compliance with incentive spirometer use" (Sinisa Vukelic, Mechanical Engineering; Alexander Kushnir, Medicine; TLO: Sara Gusik)

"Microchip with Tumor-Organoid-and-Blood-Vessel to Screen Drug Efficacy and Toxicity" (Kam Leong, BME; ZaoZao Chen, BME; Swarnali Acharyya, Medicine; TLO: Joan Martinez)

Wound Care

"Conform-a-Care: Elasticated, contouring wound dressing for optimal wound care" (Mary Boyce, Biomedical Engineering; Laura Levin, Dermatology; TLO: Joan Martinez)

 

To see all supported projects, click HERE.

2016 Call for Pre-Proposals

Columbia-Coulter Biomedical Accelerator

We are very pleased to announce that the Columbia-Coulter Translational Research Partnership is currently accepting Pre-Proposals for the next application cycle (i.e. 2017 funding). (Although Coulter Foundation funding is coming to an end, we are able to sustain the program for an additional year and are working on longer term financial support.)

All biomedical technologies with the potential to directly impact human health will be considered (e.g. therapeutic drugs and devices, medical imaging, monitoring devices, biosensors, biomaterials, and platform technologies). Most relevant are technologies in which the time to market can be achieved in 7 to 10 years. To be eligible, the project/technology must be an idea or invention based on Columbia intellectual property.

Eligible teams must include both an engineer/scientist and a clinician, and at least one PI must have a faculty appointment at Columbia. If you need an engineering or clinical collaborator, we may be able to facilitate introductions. Please email matchmaking requests to coulter@columbia.edu by November 1, 2016. 

Pre-Proposals are due by Thursday, December 1, 2016.

We very much appreciate your help amplifying the Columbia-Coulter Call for Pre-Proposals. Please feel free to forward this to any of your PIs who you think might benefit from the program. Details are below. We’re also hosting information sessions next week and in mid-October, and potential applicants are always welcome to reach out to us directly at coulter@columbia.edu.

INFO SESSION

CUMC

  • Wednesday, October 19th, 4pm, Presbyterian Hospital Building, 10th Floor, Room 204, Irving Institute Conference Room (PH-10-204) (Click HERE to RSVP)

If you have any questions, please email us at coulter@columbia.edu

For more information on the application process, click HERE

June 2015 Funded Projects

The Columbia-Coulter Translational Research Partnership is pleased to announce the newly funded projects from the Columbia-Coulter 2015-2016 cycle. Among our six funding recipients were teams in DiagnosticsHealth Care ITNeurology, and Rehabilitation/Robotics

Congratulations to the following recipients (Organized by specialty):

HEALTH CARE IT: "LabCards: Next generation clinical decision support software" John Wright, PhD, Steven Spitalnik, MD, and Jose Morales, PhD

NEUROLOGY: "uDBS: Noninvasive deep brain stimulation using focused ultrasound" Elisa Konofagou, PhD, Sameer Sheth, MD, PhD, and Christian Aurup

REHAB/ROBOTICS: "MyHand: An active hand orthosis for stroke patients" Matei Ciocarlie, PhD, and Joel Stein, MD

SCREENING/DIAGNOSTICS: "MicroClot: Device to rapidly assess antiplatelet drug efficacy for patients at risk for thrombosis" Sam Sia, PhD, and Thomas Diacovo, MD

SCREENING/DIAGNOSTICS: "SoleSound: A fully portable instrumented footwear for accurate gait analysis" Sunil Agrawal, PhD, Pietro Mazzoni, MD, and Damiano Zanotto, PhD

SCREENING/DIAGNOSTICS: "TEAM Helmet: The Transmitted Activity Monitoring Helmet: A real-time, objective, physiological means of diagnosing concussion as it happens" Barclay Morrison, PhD, and James Noble, MD 

The Columbia-Coulter partnership promotes, develops, and supports innovations aimed at improving patient care. The program provides mentoring, project management, and funding to promising translational projects with the goal of moving innovative technologies to clinical application through commercialization. The ultimate goal of this partnership is to develop healthcare solutions that address unmet or underserved clinical needs.

The Columbia-Coulter program is currently in the fourth cycle of grants within an overall $5 million of funding during a period of five years—two-thirds from the Foundation, one-third from Columbia—to projects with the highest chances of achieving a successful outcome, defined by the Foundation as a license of the technology to a commercial partner with the resources and expertise to bring the technology to market. The program, which focuses on the commercialization of medical devices, diagnostics, and healthcare IT, has jumpstarted the translation and development of biomedical technologies arising from engineering-clinical collaborations at Columbia. The Columbia-Coulter Translational Research partnership has now funded 23 projects over four years. 

To see previously funded projects from Cycles 1, 2, and 3, click HERE.

FUNDED COULTER PROJECT ENTERS LICENSING AGREEMENT

Columbia University and Ushio Inc. Enter Into Exclusive License and Research Agreements for Ultraviolet Disinfection Method to Reduce Microbial Infection. Columbia University's ultraviolet (UV) light technology, DUVS, formerly awarded Coulter funding in the 2013-2014 cycle, has been licensed by Ushio Inc., a Tokyo-based developer, manufacturer, and marketer of light sources and instruments. 

To Learn More please visit here at Columbia Technology Ventures.